EMEDKIT
EMEDKIT
Rajinder Nagar, New Delhi, Delhi
SEND SMS
SEND EMAIL

Ledipasvir 90 mg & Sofosbuvir 400 mg Tablet

Pioneers in the industry, we offer ledifos - ledipasvir 90mg and ledikast - ledipasvir 90 mg and sofosbuvir 400 mg tablets from India.

Ledifos - Ledipasvir 90mg

Ledifos - Ledipasvir 90mg
  • Ledifos - Ledipasvir 90mg
Get Best Quote
Approx. Price: Rs 14,000 / PackGet Latest Price

Product Details:

Minimum Order Quantity1 Pack
Packaging TypeBottle

We are offering a huge spectrum of Ledipasvir 90 mg & Sofosbuvir 400 mg Tablet that contains Ledipasvir and Sofosbuvir. These tablets are the combination of anti-viral medications and used in the treatment of Chronic Hepatitis C Virus (CHC) infection genotype 1. Apart from this, customers can avail this tablet from us in a stipulated time frame at very affordable rates.

Features:

• Safe consumption
• Free from impurities
• Hygienically packed

Other Details:

• This Tablets contains Ledipasvir and Sofosbuvir a formulation combination of anti-viral medications used in the treatment of Chronic Hepatitis C Virus (CHC) infection genotype 1
• This is a prescription medicine containing Ledipasvir (90mg) a viral NS5A inhibitor and Sofosbuvir (400mg) a nucleotide inhibitor of the viral RNA polymerase

Request
Callback
Yes! I am interested

Ledikast - Ledipasvir 90 Mg And Sofosbuvir 400 Mg Tablets

Ledikast - Ledipasvir 90 Mg And Sofosbuvir 400 Mg Tablets
  • Ledikast - Ledipasvir 90 Mg And Sofosbuvir 400 Mg Tablets
  • Ledikast - Ledipasvir 90 Mg And Sofosbuvir 400 Mg Tablets
Ask For Price
Product Price :Get Latest Price

LEDIKAST Tablets Specification



Brand Name LEDIKAST
Contents Ledipasvir and Sofosbuvir
Marketed by Aprazer Health Care
Manufactured by Natco Pharma Limited
Strength - Each film-coated tablet Contains 90 mg Ledipasvir and 400 mg Sofosbuvir
Form Tablets
Packing Pack of 28 Tablet

Each film-coated tablet contains 90 mg ledipasvir and 400 mg sofosbuvir. The tablet includes the following inactive ingredients colloidal silicon dioxide, copovidone, croscarmellose sodium, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. The tablet is film-coated with a coating material containing the following inactive ingredients Yellow Oxide of Iron, polyethylene glycol, polyvinyl alcohol, talc, FD&C Blue #2 and titanium dioxide IP. - www.emedkit.com

Ledipasvir The IUPAC name for ledipasvir is Methyl [(2S)-1-{(6S)-6-[5-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2azabicyclo[2.2.1] hept-3-yl]-1H-benzimidazol-6-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4] hept-5-yl}-3-methyl-


2.1 Mechanism of Action

Ledikast is a fixed-dose combination of ledipasvir and sofosbuvir which are directacting antiviral agents against the hepatitis C virus.

2.2 Pharmacodynamics

Cardiac Electrophysiology

Ledipasvir at a dose of 120 mg twice daily (2.67 times the maximum recommended dosage) and sofosbuvir 400 mg (maximum recommended dosage) and 1200 mg (three times the maximum recommended dosage) does not prolong QTc in clinical trials - www.emedkit.com


2.3 Pharmacokinetics

Absorption

The pharmacokinetic properties of ledipasvir, sofosbuvir, and the predominant circulating metabolite GS-331007 have been evaluated in healthy adult subjects and in subjects with chronic hepatitis C. Following oral administration, ledipasvir median peak concentrations were observed 4 to 4.5 hours post-dose. Sofosbuvir was absorbed quickly and the peak median plasma concentration was observed ~0.8 to 1 hour post dose. Median peak plasma concentration of GS-331007 was observed between 3.5 to 4 hours post-dose.

Based on the population pharmacokinetic analysis in HCV-infected subjects, geometric mean steady-state AUC0-24 for ledipasvir (N=2113), sofosbuvir (N=1542), and GS-331007 (N=2113) were 7290, 1320, and 12,000 ng-hr/mL. Steady-state Cmax for ledipasvir, sofosbuvir, and GS-331007 were 323, 618, and 707 ng/mL. Sofosbuvir and GS-331007 AUC0-24 and Cmax were similar in healthy adult subjects and subjects with HCV infection. Relative to healthy subjects (N=191)



Ledipasvir is >99.8% bound to human plasma proteins. After a single 90 mg dose of [14C]-ledipasvir in healthy subjects, the blood to plasma ratio of [14C]-radioactivity ranged between 0.51


Sofosbuvir is approximately 61-65% bound to human plasma proteins and the binding is independent of drug concentration over the range of 1 g/mL to 20 g/mL. Protein binding of GS-331007 was minimal in human plasma. After a single 400 mg dose of [14C]-sofosbuvir in healthy subjects, the blood to plasma ratio of 14C-radioactivity was approximately 0.7.

Request
Callback
Yes! I am interested
X

Explore more products



Reach Us
Jasminder Singh (CEO)
Ground Floor, Old Rajinder Nagar
New Delhi- 110060, Delhi, India



Call Us

Share Us

F GT L


Send E-mailSend SMS